MONALEESA-2 Studie, Überlebensvorteil mit antihormoneller Therapie (Ribociclib)
Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Wolfgang Janni, Ulm
LBA17_PR - Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
G.N. Hortobagyi, et al.
To date, this is the first report of a statistically significant and clinically meaningful OS benefit with a 1L CDK4/6i in postmenopausal pts with HR+/HER2– ABC. After a median follow-up of >6.5 y, median OS improvement was >12 mo for 1L RIB + LET vs PBO + LET.